ADMA Biologics, Inc.
ADMA
$17.02
$0.110.65%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 78.13% | 78.29% | 43.86% | 47.86% | 63.73% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 78.13% | 78.29% | 43.86% | 47.86% | 63.73% |
| Cost of Revenue | 41.19% | 14.52% | 5.86% | 19.59% | 35.59% |
| Gross Profit | 141.99% | 244.24% | 136.83% | 119.28% | 155.30% |
| SG&A Expenses | 28.88% | 12.64% | 2.16% | -14.55% | -14.42% |
| Depreciation & Amortization | -84.36% | -20.67% | 7.82% | 5.04% | 0.11% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 36.89% | 12.20% | 4.03% | 6.48% | 16.23% |
| Operating Income | 356.40% | 8,387.74% | 2,784.01% | 334.93% | 193.22% |
| Income Before Tax | 1,332.71% | 662.72% | 371.04% | -44.25% | 117.22% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 1,299.96% | 603.25% | 362.28% | -44.25% | 117.22% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 1,299.96% | 603.25% | 362.28% | -44.25% | 117.22% |
| EBIT | 356.40% | 8,387.74% | 2,784.01% | 334.93% | 193.22% |
| EBITDA | 285.80% | 2,438.34% | 1,861.89% | 496.24% | 244.57% |
| EPS Basic | 1,242.98% | 582.17% | 354.25% | -29.52% | 115.02% |
| Normalized Basic EPS | 1,278.87% | 638.55% | 362.83% | 162.60% | 114.98% |
| EPS Diluted | 1,400.00% | 533.33% | 354.25% | -30.59% | 112.50% |
| Normalized Diluted EPS | 1,259.42% | 616.76% | 354.45% | 162.60% | 114.56% |
| Average Basic Shares Outstanding | 4.13% | 4.37% | 3.13% | 11.41% | 14.71% |
| Average Diluted Shares Outstanding | 4.72% | 8.75% | 6.53% | 11.41% | 19.03% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
